Literature DB >> 27463250

p53 mutations promote proteasomal activity.

Moshe Oren1, Eran Kotler1.   

Abstract

p53 mutations occur very frequently in human cancer. Besides abrogating the tumour suppressive functions of wild-type p53, many of those mutations also acquire oncogenic gain-of-function activities. Augmentation of proteasome activity is now reported as a common gain-of-function mechanism shared by different p53 mutants, which promotes cancer resistance to proteasome inhibitors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27463250     DOI: 10.1038/ncb3392

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  15 in total

Review 1.  Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes.

Authors:  Magali Olivier; Philippe Taniere
Journal:  Curr Opin Oncol       Date:  2011-01       Impact factor: 3.645

Review 2.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

Review 3.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

Review 4.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

5.  Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.

Authors:  Dawid Walerych; Kamil Lisek; Roberta Sommaggio; Silvano Piazza; Yari Ciani; Emiliano Dalla; Katarzyna Rajkowska; Katarzyna Gaweda-Walerych; Eleonora Ingallina; Claudia Tonelli; Marco J Morelli; Angela Amato; Vincenzo Eterno; Alberto Zambelli; Antonio Rosato; Bruno Amati; Jacek R Wiśniewski; Giannino Del Sal
Journal:  Nat Cell Biol       Date:  2016-06-27       Impact factor: 28.824

Review 6.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

7.  Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Authors:  Shunsuke Kato; Shuang-Yin Han; Wen Liu; Kazunori Otsuka; Hiroyuki Shibata; Ryunosuke Kanamaru; Chikashi Ishioka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 11.205

Review 8.  Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.

Authors:  Raymond J Deshaies
Journal:  BMC Biol       Date:  2014-11-11       Impact factor: 7.431

9.  Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.

Authors:  Jiajun Zhu; Morgan A Sammons; Greg Donahue; Zhixun Dou; Masoud Vedadi; Matthäus Getlik; Dalia Barsyte-Lovejoy; Rima Al-awar; Bryson W Katona; Ali Shilatifard; Jing Huang; Xianxin Hua; Cheryl H Arrowsmith; Shelley L Berger
Journal:  Nature       Date:  2015-09-02       Impact factor: 49.962

10.  Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.

Authors:  Min-Che Tung; Po-Lin Lin; Yao-Chen Wang; Tsung-Ying He; Ming-Ching Lee; Sauh D Yeh; Chih-Yi Chen; Huei Lee
Journal:  Oncotarget       Date:  2015-12-08
View more
  3 in total

1.  Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity.

Authors:  Jin Hee Lee; Kyung-Ho Jung; Cung Hoa Thien Quach; Jin Won Park; Seung Hwan Moon; Young Seok Cho; Kyung-Han Lee
Journal:  Sci Rep       Date:  2018-08-16       Impact factor: 4.379

2.  Targeting poor proteasomal function with radioiodine eliminates CT26 colon cancer stem cells resistant to bortezomib therapy.

Authors:  Jin Hee Lee; Kyung-Ho Jung; Jin Won Park; Seung Hwan Moon; Young Seok Cho; Kyung-Han Lee
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

3.  Synthetic Lethal Drug Combinations Targeting Proteasome and Histone Deacetylase Inhibitors in TP53-Mutated Cancers.

Authors:  Shaoli Das; Xiang Deng; Kevin Camphausen; Uma Shankavaram
Journal:  Arch Cancer Biol Ther       Date:  2020
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.